Product Description
Anagliptin is an orally available, potent, selective inhibitor of dipeptidyl peptidase 4 (DPP-4), with hypoglycemic activity. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Anagliptin)
Mechanisms of Action: DPP4 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Japan
Approved Indications: None
Known Adverse Events: None
Company: Sanwa Kagaku Kenkyusho
Company Location: Asia Pacific
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Coronary Artery Disease|Type 2 Diabetes
Phase 3: Type 2 Diabetes
Phase 1: Kidney Diseases|Type 2 Diabetes
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04267601 |
SSUG | N/A |
Unknown status |
Type 2 Diabetes |
2021-03-30 |
2023-04-04 |
Primary Endpoints|Treatments|Trial Status |
|
CTR20192569 |
CTR20192569 | N/A |
Recruiting |
Type 2 Diabetes |
None |
2025-04-29 |
Patient Enrollment|Treatments|Trial Status |
|
NCT01131091 |
SK-0403-1.02US | P1 |
Completed |
Type 2 Diabetes|Kidney Diseases |
2010-11-01 |
2019-03-19 |
||
NCT01169090 |
SK-0403-2.01US | P2 |
Completed |
Type 2 Diabetes |
2011-07-01 |
2019-03-19 |
Treatments |
|
NCT00888719 |
CWP-SKD-201 | P2 |
Completed |
Type 2 Diabetes |
2010-01-01 |
2019-03-18 |
Treatments |
|
JapicCTI-070458 |
JapicCTI-070458 | P2 |
Completed |
Type 2 Diabetes |
None |
|||
NCT00532506 |
DP1001 | P2 |
Completed |
Type 2 Diabetes |
None |
2019-03-21 |
Treatments |
|
JapicCTI-132246 |
JapicCTI-132246 | P3 |
Completed |
Type 2 Diabetes |
2015-09-01 |
|||
JapicCTI-132048 |
JapicCTI-132048 | P3 |
Completed |
Type 2 Diabetes |
2014-09-01 |
|||
NCT01529541 |
CWP-DIANA-302 | P3 |
Completed |
Type 2 Diabetes |
2013-05-01 |
2019-03-19 |
Treatments |
|
NCT01529528 |
CWP-DIANA-301 | P3 |
Completed |
Type 2 Diabetes |
2012-09-01 |
2019-03-19 |
Treatments |
|
JapicCTI-090783 |
JapicCTI-090783 | P3 |
Completed |
Type 2 Diabetes |
2011-06-30 |
|||
JapicCTI-090778 |
JapicCTI-090778 | P3 |
Completed |
Type 2 Diabetes |
2011-06-30 |
|||
JapicCTI-090795 |
JapicCTI-090795 | P3 |
Completed |
Type 2 Diabetes |
2011-06-30 |
|||
JapicCTI-090923 |
JapicCTI-090923 | P3 |
Completed |
Type 2 Diabetes |
2011-02-28 |
|||
JapicCTI-101297 |
JapicCTI-101297 | P3 |
Completed |
Type 2 Diabetes |
2011-02-28 |
|||
JapicCTI-101237 |
JapicCTI-101237 | P3 |
Completed |
Type 2 Diabetes |
2011-01-31 |
|||
JapicCTI-101159 |
JapicCTI-101159 | P3 |
Completed |
Type 2 Diabetes |
2010-10-31 |
|||
NCT04810507 |
ACACIA | P4 |
Completed |
Type 2 Diabetes |
2020-09-02 |
2021-03-25 |
||
NCT02330406 |
REASON | P4 |
Completed |
Coronary Artery Disease |
2018-01-01 |
2019-08-30 |
Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |